drugset

drugset / Trial / NCT06578520

Effect of the Use of Dapagliflozin in Patients With Refractory Heart Failure

NCT06578520 ↗

Phase 4 Recruiting 31 enrolled Fundación para la Investigación del Hospital Clínico de Valencia

RandomizedCrossoverOpen-labelTreatment

Summary

Cross-over, 2-sequence, 2-treatment, 2-period single-centre, phase IV, randomized, open label study.

Timeline

Start: 2024-07-30
Primary completion: 2025-12-01
Completion: 2025-12-31

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Dapagliflozin	Small molecule	10 mg	Oral

Indications